Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | ERN1 | O75460 | 1/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 8/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | GRK6 | P43250 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7190826 | 0.86 | TSHR (0.64) | ALDH1A1TSHRCYP3A4RECQLMAPT | |
| SCHEMBL17117159 | 0.84 | TSHR (0.62) | ALDH1A1TSHRCYP3A4RECQLMAPT | |
| SCHEMBL2377563 | 0.83 | DAPK3 (0.56) | ALDH1A1TSHRCYP3A4RECQLMAPT | |
| SCHEMBL10475465 | 0.81 | ALDH1A1 (0.51) | ALDH1A1TSHRCYP3A4RECQLMAPT | |
| SCHEMBL30474720 | 0.80 | MAPT (0.73) | ALDH1A1TSHRCYP3A4ERN1MAPT | |
| SCHEMBL717629 | 0.80 | MAPT (0.73) | ALDH1A1TSHRCYP3A4ERN1MAPT | |
| SCHEMBL9999827 | 0.79 | ALDH1A1 (0.56) | ALDH1A1TSHRCYP3A4RECQLMAPT | |
| SCHEMBL15203036 | 0.77 | CRHBP (0.58) | ALDH1A1TSHRCYP3A4RECQLMAPT | |
| SCHEMBL1514401 | 0.77 | CRHBP (0.58) | ALDH1A1TSHRCYP3A4RECQLMAPT | |
| SCHEMBL20364812 | 0.76 | ALDH1A1 (0.53) | ALDH1A1TSHRCYP3A4RECQLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1626532-A | Amide compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-06-15 | — | — | CN | disclosed |
| US-20040266774-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-30 | — | — | US | disclosed |
| CN-1170826-C | Amide compound | ����ҩƷ��ҵ��ʽ���� | 2004-10-13 | — | — | CN | disclosed |
| US-6770667-B1 | N-((IMIDAZOLYL)-PHENYL)-FLUORENE-1-CARBOXAMIDE DERIVATIVES; 5-HYDROXYTRYPTAMINE (5-HT) ANTAGONISTS; PSYCHOLOGICAL, NERVOUS SYSTEM, EATING, BRAIN AND SLEEP DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-03 | — | — | US | disclosed |
| CN-1376153-A | Amide compound | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-10-23 | — | — | CN | disclosed |
| EP-1216240-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001025229-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266774-A1 | Amide compounds | TPH1, HTR1A, HTR5A | ALDH1A1 386/4885TSHR 112/4885CYP3A4 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.